Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
The patient missed a dose of VIVOTIF and took it a day later; Case reference number US-BN-2025-000030 is a spontaneous case report initially received from a nurse via Communication (reference number: USBAV25-0056) on 08-Jan-2025 and concerns a 70-years-old female patient. The patient's relevant medical history and concomitant medications were not provided. On an unspecified date, the patient took dose of Vivotif vaccine (batch number: unknown) at an unknown dose, orally for unknown indication. On an unspecified date, reported as Tuesday morning, the patient took second dose of Vivotif vaccine (batch number: unknown) at an unknown dose, orally. The patient was scheduled to take the second dose of Vivotif on Monday, but instead, patient took it a day later. (explicitly coded as 'Inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A 70-year-old female patient was scheduled to take the second dose of Vivotif for unknown indication on Monday, but instead, patient took it a day later, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 70-year-old female patient was scheduled to take the second dose of Vivotif for unknown indication on Monday, but instead, patient took it a day later, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None